| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DARC |
| Uniprot No | Q16570 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-336aa |
| 氨基酸序列 | MGNCLHRAELSPSTENSSQLDFEDVWNSSYGVNDSFPDGDYGANLEAAAPCHSCNLLDDSALPFFILTSVLGILASSTVLFMLFRPLFRWQLCPGWPVLAQLAVGSALFSIVVPVLAPGLGSTRSSALCSLGYCVWYGSAFAQALLLGCHASLGHRLGAGQVPGLTLGLTVGIWGVAALLTLPVTLASGASGGLCTLIYSTELKALQATHTVACLAIFVLLPLGLFGAKGLKKALGMGPGPWMNILWAWFIFWWPHGVVLGLDFLVRSKLLLLSTCLAQQALDLLLNLAEALAILHCVATPLLLALFCHQATRTLLPSLPLPEGWSSHLDTLGSKS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为假设性示例，仅供参考。建议通过学术数据库(如PubMed、Google Scholar)验证文献真实性：
1. **《Structural characterization of the Duffy antigen/receptor for chemokines (DARC) recombinant protein》**
- 作者：Peiper, S.C. et al.
- 摘要：研究通过重组技术表达DARC蛋白，解析其与趋化因子(如IL-8)及疟原虫蛋白的结合域，揭示其双重功能的结构基础。
2. **《DARC extracellular domain recombinant protein inhibits Plasmodium vivax invasion in vitro》**
- 作者：Miller, L.H. et al.
- 摘要：体外实验表明，重组DARC蛋白可阻断间日疟原虫入侵红细胞，为基于DARC的疟疾治疗策略提供依据。
3. **《DARC recombinant protein modulates neutrophil migration in sepsis models》**
- 作者：Lee, J.S. et al.
- 摘要：在败血症小鼠模型中，重组DARC蛋白通过调控趋化因子清除减轻炎症反应，提示其作为抗炎治疗靶点的潜力。
4. **《Duffy antigen receptor facilitates breast cancer metastasis via interaction with chemokines》**
- 作者：Addison, C.L. et al.
- 摘要：发现肿瘤细胞表达的DARC蛋白通过结合趋化因子促进血管生成和转移，重组DARC或可抑制此过程。
**注意**：以上为示例，实际文献需根据具体研究方向检索。真实文献可能涉及疟疾机制、炎症调控或癌症研究，建议结合关键词“Duffy antigen/receptor”、“recombinant DARC”、“Plasmodium”、“chemokine”等查询。
**Background of DARC Recombinant Protein**
The Duffy Antigen/Receptor for Chemokines (DARC), also known as ACKR1 or CD234. is a conserved transmembrane protein initially identified for its dual role as a blood group antigen and a receptor for Plasmodium vivax malaria parasites. Expressed on erythrocytes and endothelial cells, DARC binds pro-inflammatory chemokines (e.g., CXCL8. CCL2) and regulates their bioavailability, modulating leukocyte trafficking and inflammatory responses. Its absence in Duffy-negative individuals confers resistance to P. vivax infection, highlighting its medical significance.
Recombinant DARC protein is engineered in vitro using expression systems (e.g., mammalian, insect, or bacterial cells) to produce soluble or membrane-bound forms for research and therapeutic applications. This recombinant approach enables precise control over protein structure, often incorporating tags (e.g., Fc, His-tag) for purification and detection. By omitting transmembrane domains, soluble DARC variants mimic extracellular domains, facilitating studies on chemokine interactions and signaling.
DARC recombinant protein is widely used to investigate chemokine networks, host-pathogen interactions, and inflammatory diseases. It serves as a tool to block chemokine-mediated processes in cancer or autoimmune models and to study malaria invasion mechanisms. Additionally, structural studies leveraging recombinant DARC have elucidated binding interfaces with chemokines and pathogens, aiding drug and vaccine design. Recent research also explores its role in HIV pathogenesis and sepsis, underscoring its multifaceted relevance.
Overall, recombinant DARC provides a versatile platform to dissect its biological functions and therapeutic potential, bridging gaps between basic research and clinical innovation.
×
